141 related articles for article (PubMed ID: 10425314)
1. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
4. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
5. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
6. Serum CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Jalkanen S
Leuk Lymphoma; 1999 May; 33(5-6):433-40. PubMed ID: 10342571
[TBL] [Abstract][Full Text] [Related]
7. Origin and function of circulating CD44 in non-Hodgkin's lymphoma.
Ristämaki R; Joensuu H; Grön-Virta K; Salmi M; Jalkanen S
J Immunol; 1997 Mar; 158(6):3000-8. PubMed ID: 9058839
[TBL] [Abstract][Full Text] [Related]
8. Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma.
Mäenpää H; Ristamäki R; Virtamo J; Franssila K; Albanes D; Joensuu H
Leuk Lymphoma; 2000 May; 37(5-6):585-92. PubMed ID: 11042519
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
11. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer.
Baek JM; Jin Q; Ensor J; Boulbes DR; Esteva FJ
Breast Cancer Res Treat; 2011 Dec; 130(3):1029-36. PubMed ID: 21830016
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD44 and CD44v6 and prognosis in children with B-cell acute lymphoblastic leukemia.
Amirghofran Z; Asiaee E; Kamazani FM
Asia Pac J Clin Oncol; 2016 Sep; 12(3):e375-82. PubMed ID: 25227983
[TBL] [Abstract][Full Text] [Related]
14. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients.
Mayer S; zur Hausen A; Watermann DO; Stamm S; Jäger M; Gitsch G; Stickeler E
J Cancer Res Clin Oncol; 2008 Nov; 134(11):1229-35. PubMed ID: 18438684
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
Khalifa KA; Alkilani AA; Ismail H; Soliman MA
J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
17. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD44 splice variants in metastasizing human breast cancer.
Martin S; Jansen F; Bokelmann J; Kolb H
Int J Cancer; 1997 Aug; 74(4):443-5. PubMed ID: 9291436
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
[TBL] [Abstract][Full Text] [Related]
20. Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment.
Beksaç M; Arat M; Akan H; Koç H; Ilhan O; Ozcan M
Cancer; 2000 Oct; 89(7):1474-81. PubMed ID: 11013360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
